About this trial
The goal of this pilot study is to learn if a digitally enhanced peer doula program for people with perinatal substance use disorders (PSUD) is feasible and acceptable to patients and staff at two clinics.
Participants will include staff members, such as healthcare providers, recovery support doulas, and administrators, who work at one of the two clinics. It will also include PSUD patients receiving care through the digitally enhanced peer doula program.
Participants will be asked to complete short surveys and take part in a one-time interview with research staff.
This study will also explore engagement in perinatal substance use disorder treatment and prenatal and postpartum visits.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
18 years of age or older.
Provider (including MD, CNM, DO, PA, NP, nurse, medical assistant, behavioral health clinician, social worker, lactation consultant and/or other clinical roles that provide care to patients).
Peer doulas.
Administrator (including front desk staff, scheduler, clinic and/or team manager).
Disqualifiers
Unwilling or unable to provide consent
Currently detained in jail, prison, residential substance use treatment facility, or other overnight facility as required by court of law; or have pending legal action that could prevent participating in study activities
18 years of age or older
Patient of the participating site who is eligible to receive prenatal, postpartum, or delivery services
Trial population
Staff participants and patient participants will be selected from two participating clinical sites that have implemented the digitally enhanced peer doula model of care.
Trial design
Cohort
Other
Treatments tested in this trial
Digitally Enhanced Peer Doula Model of Care
Other interventionIn the digitally enhanced peer doula model of care, patients with perinatal substance use disorder are partnered with a recovery support peer doula who is able to provide synchronous or asynchronous support. This support can include in-person and text-based and/or telehealth support, in addition to assistance scheduling and arranging transport to appointments for both SUD and peripartum care, and assisting with access to food, transportation and housing. Additionally, these patients are offered a free smartphone and data plan for pregnancy and one-year postpartum.
Treatment groups
Trial outcomes
Primary outcomes
Feasibility of Intervention Measure (FIM)
Site staff participants will complete the FIM, a 4-item survey, that examines the feasibility of implementing the digitally enhanced peer doula model in routine obstetric settings. Using a five-point Likert scale, the FIM has 4 items examining whether an innovation is implementable, possible, doable, and easy to use. Items are scored using a Likert scale that ranges from 1 (Completely Disagree) to 5 (Completely Agree). Scales are created by averaging responses, with total score values ranging from 1 to 5. Higher scores indicate greater feasibility. Two versions of the FIM will be completed by Site staff participants. The first will collect data on the acceptability of providing smartphones to patients. The second version of the FIM will assess the acceptability of the peer doula component of the model.
Acceptability of Intervention Measures (AIM)
Site staff and patient participants will complete the AIM, a 4-item survey, that assesses the acceptability of the digitally enhanced peer doula model in routine obstetric settings. The survey asks participants to rate the acceptability of the model from completely disagree to completely agree. Using a five-point Likert scale, the AIM has 4 items examining whether an innovation meets participant approval, is appealing, is welcomed, and is liked. Items are scored using a Likert scale that ranges from 1 (Completely Disagree) to 5 (Completely Agree). Scales are created by averaging responses, with total score values ranging from 1 to 5. Higher scores indicate greater acceptability. Two versions of the AIM will be completed by patient participants. The first will collect data on the acceptability of providing smartphones to patients. The second version of the AIM will assess the acceptability of the peer doula component of the model. Site staff will only complete the second version. .
Secondary outcomes
Number of Prenatal Obstetric Visits
The number of prenatal visits will be abstracted from the EHR to explore the impact of the digitally enhanced peer doula model. Depending on the distribution of the number of visits, either mean or median visits will be compared between patient participants and the historical control cohort.
Number of Postpartum Obstetric Visits
The number of postpartum visits will be abstracted from the EHR to explore the impact of the digitally enhanced peer doula model. Depending on the distribution of the number of visits, either mean or median visits will be compared between patient participants and the historical control cohort.
Engagement in substance use disorder (SUD) treatment
Engagement in substance use disorder (SUD) treatment will be assessed via the Oregon Hope Engagement in Addiction Treatment Survey (OR HOPE). This will be measured by evaluating the percentage of patients reporting participation in SUD services before and after exposure to the model. Items measured will be the following: * Types of SUD treatment received * Frequency of SUD treatment
Engagement in Peer Doula Support
Sites will abstract data from each peer doula contact with study participants. This data will include the following: 1. Modality of each encounter (e.g., virtual, phone-based, or in-person) 2. Location of contact (e.g., obstetric clinic, other healthcare setting, patient home, or community) 3. Types of support provided (e.g., recovery, pregnancy, postpartum, housing, transportation, food, lactation, or other).
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Trustees of Dartmouth College
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
This trial is not recruiting at the moment. You can still explore other options: